ID: ALA2417553

Max Phase: Preclinical

Molecular Formula: C18H16N2

Molecular Weight: 260.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cncc(Cc2ccc(-c3ccccc3)nc2)c1

Standard InChI:  InChI=1S/C18H16N2/c1-14-9-16(12-19-11-14)10-15-7-8-18(20-13-15)17-5-3-2-4-6-17/h2-9,11-13H,10H2,1H3

Standard InChI Key:  FLLIVPRKOUZFTG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 260.34

Molecular Weight (Monoisotopic): 260.1313

AlogP: 4.04

#Rotatable Bonds: 3

Polar Surface Area: 25.78

Molecular Species: NEUTRAL

HBA: 2

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.93

CX LogP: 4.18

CX LogD: 4.16

Aromatic Rings: 3

Heavy Atoms: 20

QED Weighted: 0.71

Np Likeness Score: -0.65

References

1. Emmerich J, Hu Q, Hanke N, Hartmann RW..  (2013)  Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.,  56  (15): [PMID:23869452] [10.1021/jm400240r]

2. Hu Q, Kunde J, Hanke N, Hartmann RW..  (2015)  Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.,  96  [PMID:25874338] [10.1016/j.ejmech.2015.04.013]

3. Emmerich J, van Koppen CJ, Burkhart JL, Hu Q, Siebenbürger L, Boerger C, Scheuer C, Laschke MW, Menger MD, Hartmann RW..  (2017)  Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.,  60  (12): [PMID:28570067] [10.1021/acs.jmedchem.7b00437]

Source

Source(1):

• Scientific Literature